Arvinas, Inc. (NASDAQ:ARVN – Free Report) – Stock analysts at Wedbush raised their FY2023 earnings per share estimates for Arvinas in a report issued on Tuesday, November 7th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($4.94) per share for the year, up from their prior estimate of ($5.53). Wedbush has a “Outperform” rating and a $24.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($6.05) per share. Wedbush also issued estimates for Arvinas’ Q4 2023 earnings at ($0.97) EPS, Q1 2024 earnings at ($0.98) EPS, Q2 2024 earnings at ($0.99) EPS, Q3 2024 earnings at ($1.01) EPS, Q4 2024 earnings at ($1.40) EPS, FY2024 earnings at ($4.38) EPS, FY2025 earnings at ($4.46) EPS, FY2026 earnings at ($4.39) EPS and FY2027 earnings at ($4.85) EPS.
Arvinas (NASDAQ:ARVN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.58) by $0.40. The firm had revenue of $34.60 million for the quarter, compared to analyst estimates of $39.58 million. Arvinas had a negative net margin of 185.09% and a negative return on equity of 59.18%. The company’s revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.24) EPS.
Arvinas Stock Performance
Shares of ARVN stock opened at $14.99 on Friday. Arvinas has a 52-week low of $13.57 and a 52-week high of $57.96. The stock has a market cap of $824.90 million, a price-to-earnings ratio of -2.71 and a beta of 1.86. The firm’s 50-day moving average is $19.72 and its 200-day moving average is $23.12.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Pictet Asset Management SA lifted its position in Arvinas by 9.4% in the first quarter. Pictet Asset Management SA now owns 531,080 shares of the company’s stock worth $14,509,000 after buying an additional 45,799 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Arvinas by 57.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 5,306 shares of the company’s stock valued at $145,000 after purchasing an additional 1,936 shares during the last quarter. SG Americas Securities LLC raised its position in Arvinas by 79.8% in the 2nd quarter. SG Americas Securities LLC now owns 57,388 shares of the company’s stock worth $1,424,000 after purchasing an additional 25,471 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Arvinas by 6.1% in the second quarter. Allspring Global Investments Holdings LLC now owns 36,579 shares of the company’s stock worth $908,000 after purchasing an additional 2,091 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Arvinas by 35.5% during the first quarter. Russell Investments Group Ltd. now owns 52,470 shares of the company’s stock valued at $1,433,000 after buying an additional 13,755 shares during the period. 86.33% of the stock is owned by hedge funds and other institutional investors.
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
- Five stocks we like better than Arvinas
- Which Wall Street Analysts are the Most Accurate?
- Data giants MongoDB and Snowflake just got upgraded
- The 3 Best Fintech Stocks to Buy Now
- Plug Power at tipping point; it’s make or break time for hydrogen
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.